DENTSPLY SIRONA (NASDAQ:XRAY) Stock Gets Downgrade from Zacks Research

DENTSPLY SIRONA (NASDAQ:XRAY) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Monday, Zacks reports.

A number of other analysts have also issued reports on the stock. Bank of America reissued a “buy” rating on shares of DENTSPLY SIRONA in a research report on Friday. Leerink Partners lowered their price objective on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 14th. Barclays boosted their price objective on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a research report on Monday, August 24th. BMO Capital Markets dropped their price objective on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating on the stock in a research note on Thursday, September 17th. Finally, Mizuho cut their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, October 22nd. Three investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $12.42.

DENTSPLY SIRONA Stock Up 1.7%

NASDAQ:XRAY opened at $9.70 on Monday. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -15.64, a PEG ratio of 1.36 and a beta of 0.87. DENTSPLY SIRONA has a 1-year low of $8.14 and a 1-year high of $14.76. The company has a current ratio of 1.63, a quick ratio of 1.04 and a debt-to-equity ratio of 1.47. The business’s fifty day moving average price is $9.54 and its 200 day moving average price is $11.25.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.02). DENTSPLY SIRONA had a positive return on equity of 20.21% and a negative net margin of 3.38%. The business had revenue of $836.00 million for the quarter, compared to analyst estimates of $861.68 million. During the same quarter in the previous year, the business posted $0.37 earnings per share. The company’s revenue was down 7.5% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. On average, sell-side analysts forecast that DENTSPLY SIRONA will post 1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of XRAY. BlackRock Inc. acquired a new stake in shares of DENTSPLY SIRONA during the 2nd quarter valued at about $283,405,000. Southpoint Capital Advisors LP bought a new stake in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $116,000,000. Edmond DE Rothschild Holding S.A. acquired a new position in DENTSPLY SIRONA in the second quarter worth approximately $47,780,000. Dimensional Fund Advisors LP increased its holdings in DENTSPLY SIRONA by 31.4% in the first quarter. Dimensional Fund Advisors LP now owns 3,559,388 shares of the medical instruments supplier’s stock worth $41,284,000 after buying an additional 850,261 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY bought a new position in DENTSPLY SIRONA during the second quarter valued at approximately $39,775,000. 95.70% of the stock is owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc. develops, manufactures and markets products and technologies for dental professionals. Its portfolio includes dental equipment and imaging systems, digital dentistry and CAD/CAM solutions, dental implants, endodontic and restorative products, and supplies used in preventive care. The company serves dental practices, laboratories and other customers around the world. Its products support a range of clinical activities, including diagnosis, treatment planning, restorative dentistry and oral hygiene.